DSP Healthcare Fund
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Growthvine rating: 5/5 — ranked #7 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹44.41 (as of 2026-10-01) |
|---|
| AUM | ₹3,639 Cr |
|---|
| Expense ratio | 1.64% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Chirag Dagli |
|---|
| Exit load | 0.5% for redemption within 1 month |
|---|
Performance & risk
| 5-year annualised return | 13.69% |
|---|
| Sharpe ratio | 0.99 |
|---|
| Standard deviation | 14.89% |
|---|
| Max drawdown | −22.08% |
|---|
| Alpha | 0.64 |
|---|
| Beta | 0.84 |
|---|
Over 5 years, captured 89.4% of NIFTY Pharma's upside and 79.8% of its downside.
Market cap allocation
| Large cap | 29.5% |
|---|
| Mid cap | 15.7% |
|---|
| Small cap | 54.8% |
|---|
Concentration
| Top 5 holdings | 38.0% |
|---|
| Top 10 holdings | 61.4% |
|---|
| Total holdings | 31 |
|---|
Top holdings
- Ipca Laboratories Ltd. — 8.7%
- Sun Pharmaceutical Industries Ltd. — 7.9%
- Sai Life Sciences Limited — 7.4%
- Cipla Ltd. — 7.3%
- Apollo Hospitals Enterprises Ltd. — 6.5%
- Gland Pharma Limited — 6.0%
- Globus Medical Inc — 5.4%
- Divis Laboratories Ltd. — 4.2%
- Alkem Laboratories Limited — 4.1%
- Cohance Lifesciences Limited — 3.8%
Top sectors
- Pharma & Biotech — 66.4%
- Healthcare — 20.5%
- Global Equity — 9.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 13.3% | Q1 (Top) | #11 of 76 |
| 2025 | −5.8% | Q4 (Bottom) | #61 of 69 |
| 2024 | 40.7% | Q1 (Top) | #8 of 58 |
| 2023 | 35.0% | Q3 | #27 of 48 |
| 2022 | −7.8% | Q3 | #34 of 46 |